Clover Health interim CFO Thornton sells $78,032 in shares

Clover Health Investments' Interim CFO, Joseph Clay Thornton, recently sold 17,775 shares of the company's Class A Common Stock on August 17, 2026. The transaction, valued at $78,032, was completed at a weighted average price of $4.39, with individual trades occurring within a price range of $4.29 to $4.39. The sale occurred as Thornton aimed to fulfill tax withholding requirements tied to the vesting of his restricted stock units (RSUs).

Clover Health's RSU grants, initially awarded on February 16, 2024, mandated Thornton to sell shares to cover tax obligations. The RSUs, which originally included a 6.25% vesting on August 16, 2026, are set to vest in 6.25% increments each quarter, with the final vesting scheduled for February 16, 2028, contingent upon Thornton's continued employment.

Post these transactions, Thornton directly owns 1,249,526 shares of the company's Class A Common Stock. Investors interested in further details about Clover Health's financial health and future outlook can refer to the company's Pro Research Report, which covers CLOV and over 1,400 other US equities on InvestingPro. Meanwhile, Clover Health announced its second-quarter 2026 financial results, which exceeded Wall Street expectations, with adjusted earnings of 5 cents per share compared to the anticipated 4 cents per share.

Revenue for the quarter reached $743.2 million, surpassing analysts' projections of $728.27 million, a 56% increase from the previous year. Additionally, Clover Health raised its full-year outlook, which was well-received by the market, evidenced by the positive after-hours trading response.